Tanaka et al. showed that immune complexes increased CD80/86 expression on monocyte lineages, rendering them sensitive to abatacept (75) which might explain the strong efficacy of abatacept in ACPA positive RA patients. This evidence concerns the gene PRTN3 and rheumatoid arthritis.